Vatreptacog alfa is a recombinant hFVIIa analog, differing from native FVIIa by three amino acid substitutions (V158D, E296V and M298Q) in the protease domain. Vatreptacog alfa exhibits enhanced tissue factor-independent enzymatic activity toward activated platelets. Vatreptacog alfa can be used in the research of hemophilia[1].
Target:
Drug Derivative,Factor VIIa
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
